Naibec Completes Facility with 300 Billion KRW Sales Scale for Essential Implant Materials: "Proactive Response to Increased US and China Demand"

Naibec has completed the establishment of its second factory, increasing its production capacity by more than six times. While the existing first factory was capable of producing implant core materials worth up to 50 billion KRW annually, the new factory can produce up to 300 billion KRW worth annually.

Naibec announced on the 27th that the construction of its second bio-material production facility located in Jincheon-gun, Chungbuk, has been completed, and it has begun the certification process for GMP (Good Manufacturing Practice). The second factory can produce up to approximately 15 million vials of bio-materials annually.

This year, Naibec is pursuing the establishment of a local corporation in the United States to expand sales, FDA approval for new products, and clinical trials in China. Through the second factory, Naibec will be able to proactively respond to an increase in orders in the future.

With the extension of the European MDD (Medical Device Directive) scheduled for the second half of this year, sales expansion in Europe is also expected. Domestic certification for new products such as ‘Pepticol EasyGraft’ and ‘Growth Factor-Containing Bone Graft Material,’ as well as final approval stages for overseas permits for existing products like ‘Collagen Barrier Membrane’ and ‘Collagen Composite Implant Material,’ are underway, enabling flexible responses to diversified demand for core implant materials.

Along with expanding production capacity, Naibec is upgrading its quality management system by introducing a new production process system. To this end, it has newly recruited production experts from outside the company and is establishing a mass production system for high-quality essential implant materials at a level higher than before.

A Naibec representative stated, “The core implant materials produced and sold by Naibec are essential products for implant procedures, and global demand is steadily increasing due to the aging population. Naibec leads global supply by signing contracts with top-tier global implant companies such as Straumann, Nobel Biocare, and Keystone Dental, and sales are steadily increasing.”

He added, “Sales growth is expected to accelerate in the major European market from the second half of this year, and since various measures to expand sales in China have been pursued, significant sales growth is anticipated. The establishment of a corporation to target the U.S. market is also progressing smoothly, and with the full-scale operation of the second factory as a turning point, sales of bio-materials will expand significantly.”

This content was produced with the assistance of AI translation services.